Get the latest content and program updates via The Insider from Life Time.
An 18-month congressional investigation turned up plenty of dirt on the FDA’s dealings with Biogen during the agency’s controversial approval of the company’s Alzheimer’s drug, but its recommendations suggest the status quo will likely remain unchanged.
While the Federal Trade Commission works to tighten regulations on the funeral industry, which often uses obscure pricing policies to prey on grief-stricken mourners, seniors like me need to start thinking more seriously about how we want to be laid to rest.
Elderly patients are often tagged with a “failure to thrive” label when doctors simply don’t want to spend the time and energy to determine a specific diagnosis. While leading geriatricians continue to argue against the designation, others point to its more salutary effects.
As Big Pharma continues to flail away on the Alzheimer’s front, new research increasingly turns toward identifying lifestyle changes that can lower the risk of falling prey to the disease.